Amendment No. 3 to License Agreement between Stanford University and Histogenics Corporation
Stanford University and Histogenics Corporation have agreed to a third amendment to their existing license agreement, originally effective April 15, 2001, regarding technology for the restoration of articular cartilage matrix. This amendment, effective May 1, 2009, changes a specific date in Section 2.6(A) of a previous amendment. All other terms of the original agreement and prior amendments remain unchanged. The amendment also allows electronic signatures to be used as valid and enforceable. Both parties have signed the amendment through their authorized representatives.
Exhibit 10.24
CONFIDENTIAL TREATMENT REQUESTED
AMENDMENT NO. 3
TO THE
LICENSE AGREEMENT EFFECTIVE 04/15/2001
BETWEEN
STANFORD UNIVERSITY
AND
HISTOGENICS CORPORATION
Effective as of May 1, 2009, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Histogenics Corporation a Delaware company having a primary place of business at 830 Winter Street, Waltham MA 02451, agree as follows:
| 1. | BACKGROUND |
Stanford and Histogenics are parties to a License Agreement effective April 15, 2001 (“Original Agreement”) covering Restoration of Articular Cartilage Matrix disclosed in Stanford Docket S98-181.
Stanford and Histogenics wish to amend the Original Agreement to change the date in section 2.6(A) ****.
| 2. | AMENDMENT |
Section 2.6(A) of the Second Amendment dated January 15, 2006 shall be amended as follows:
Replace the third bullet under Section 2.6(A) to read as follows: ****
| 3. | OTHER TERMS |
| 3.1 | All other terms of the Original Agreement, First and Second amendments remain in full force and effect. |
| 3.2 | The parties to this document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this |
****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
CONFIDENTIAL TREATMENT REQUESTED
| document in a court of law based solely on the absence of an original signature. |
IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 3 in duplicate originals by their duly authorized officers or representatives.
| THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | ||
| Signature: | /s/ Katharine Ku | |
| Name: | Katharine Ku | |
| Title: | Director Technology Licensing | |
| Date: | May 8, 2009 | |
| Histogenics Corporation | ||
| Signature: | /s/ F. Ken Andrew | |
| Name: | F. Ken Andrew | |
| Title: | CEO & President | |
| Date: | May 6, 2009 | |
